IN THE DOUBLE-BLIND, RANDOMIZED COMPACTa STUDY OF 889 PATIENTS, SINGULAIR WITH BUDESONIDE PROVIDED EFFICACY COMPARABLE TO DOUBLING THE DOSE OF BUDESONIDE8a,b
Adapted from Price DB et al Thorax 2003;58:211–216; Data on file, MSD.
See Study Design C
SINGULAIR WITH AN INHALED STEROID PROVIDED SIGNIFICANTLY BETTER ASTHMA CONTROL THAN A STEROID ALONE (p=0.05)13,d,e
In the CASIOPEA13f study of 639 asthmatic adults, SINGULAIR with an ICS provided significantly better asthma control than a steroid alone.
Adapted from Vaquerizo MJ et al Thorax 2003;58:204–211.
See Study Design B
PRESCRIBE SINGULAIR WITH AN INHALED STEROID
Asthma symptoms and control in this study:
Improved independent of patient's usual budesonide dose13
Improved in patients with mild to moderate asthma13
Complementary effect:
SINGULAIR inhibits the important leukotriene pathway of asthmatic inflammation.7–9
Steroids do not block the formation of leukotrienes in the airways of asthmatics.9–12
aCOMPACT=Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy8 bPatients were not receiving SINGULAIR to treat allergic rhinitis.8 dImproved asthma control was defined as a decrease in the percentage of asthma exacerbation days.13 ep=0.03 vs. budesonide with placebo.13 fCASIOPEA=Capacidad de Singulair Oral en la Prevención de Exacerbaciones Asmáticas13 gPrimary endpoint (% of asthma exacerbation days) includes 625 of 639 patients randomized. A 16-week treatment period followed a 2-week run-in period.13 hRescue therapy= beta2-agonist use.13
